Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 18, 2012

View Archived Issues

Citrulline could serve as a new biomarker of Leigh's disease

U.S. researchers prepare new antimicrobial agents

Nerviano Medical Sciences presents novel B-raf inhibitors

Promising in vitro and in vivo results reported for novel dual c-Met/Ron inhibitor

New GlyT-1 inhibitors disclosed by Taisho Pharmaceutical

Phase IIb study confirms feasibility of safe vaccination against dengue

Novel topical antiviral plant extract for HSV

Janssen Pharmaceutica patents new alpha7 receptor modulators

Novel nicotinic acetylcholine alpha7 receptor modulators disclosed by Lupin

Trana Discovery identifies antibacterial target tRNA

Bionomics acquires Biogen's oncology spin-off

JASPAC1 01 phase III interim study results to be published

TB Alliance presents data for their next-generation tuberculosis drug candidate

Sunovion Pharmaceuticals launches Latuda in Canada

Targacept discontinues development of ADHD drug candidate

Life Technologies and Bristol-Myers Squibb collaborate on companion diagnostics

Merck KGaA voluntarily withdraws European application for Erbitux in NSCLC

Vasopharm's VAS-203 demonstrates safety and efficacy in traumatic brain injury trial

Ablynx reports clinical results for inhaled Nanobody in RSV infection

New NIH clinical trial network commences trial in spinal muscular atrophy

Novel mGlu5 receptor PAM developed by Janssen for the treatment of schizophrenia

Immune Targeting Systems reports clinical data for influenza A vaccine

Anthera to advance blisibimod into phase III development

Rib-X Pharmaceuticals' delafloxacin awarded QIDP status

NIH awards grant to fund research of allosteric inhibitors in acute lung injury